Hanlim Pharmaceutical launched the improvement product of the xerophthalimia treatment ‘Restasis Eye Drop’ for the first time in Korea

Hanlim Pharm (CEO Jae-yoon Kim) completed developing an improved product of the xerophthalimia treatment ‘Restasis Eye Drop’ (generic name: Cyclosporine) for the first time in Korea, and launched it with the title named ‘Tsporine Eye Drop’.

Hanlim Pharm acquired the Investigational New Drug (IND) approval from the Ministry of Food and Drug Safety on January 2012, successfully completed its Cli...